Skip to main content
Clinical Trials/EUCTR2013-003564-31-DE
EUCTR2013-003564-31-DE
Active, not recruiting
Phase 1

Multicentre, Retrospective and Prospective Study to Assess Long Term Outcomes of Chelator-Based Treatment With Trientine in Wilson Disease Patients Withdrawn from Therapy With d-Penicillamine

nivar B.V.0 sites90 target enrollmentOctober 22, 2013

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
nivar B.V.
Enrollment
90
Status
Active, not recruiting
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 22, 2013
End Date
TBD
Last Updated
7 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
nivar B.V.

Eligibility Criteria

Inclusion Criteria

  • \- Patients aged 1 year to 90 years of age at initiation of treatment with trientine.
  • \- Physician established diagnosis of Wilson disease based on a Ferenci score \> 3 at the date of diagnosis.
  • \- Documented treatment with d\-Penicillamine, withdrawal of treatment with d\- Penicillamine, followed by treatment with trientine for at least 6 months at date of informed consent.
  • \- Able/willing to provide written informed consent.
  • For enrolment in the prospective part:
  • \- Enrolment in the retrospective part of the study.
  • \- On\-going treatment with trientine.
  • \- Negative pregnancy test.
  • \- Able/willing to provide written informed consent.
  • Are the trial subjects under 18? yes

Exclusion Criteria

  • \- Incomplete history of medication use for trientine from initial diagnosis to latest follow up.
  • \- Unavailable outcome data for hepatic and neurological course of disease at initiation of treatment with trientine and at least 1 time point post\-initiation of treatment with trientine.
  • For enrolment in the prospective part:
  • \- Hypersensitivity to trientine
  • \- Severe anaemia.

Outcomes

Primary Outcomes

Not specified

Similar Trials